CU20200051A7 - Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 - Google Patents

Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5

Info

Publication number
CU20200051A7
CU20200051A7 CU2020000051A CU20200051A CU20200051A7 CU 20200051 A7 CU20200051 A7 CU 20200051A7 CU 2020000051 A CU2020000051 A CU 2020000051A CU 20200051 A CU20200051 A CU 20200051A CU 20200051 A7 CU20200051 A7 CU 20200051A7
Authority
CU
Cuba
Prior art keywords
bicyclic heterocyclic
prmt5 inhibitors
components replaced
heterocyclic components
replaced
Prior art date
Application number
CU2020000051A
Other languages
English (en)
Other versions
CU24621B1 (es
Inventor
Balasaheb Arjun Gore
Ganesh Bhausaheb Gudade
Anil Kashiram Hajare
Rajender Kumar Kamboj
Chaitanya Prabhakar Kulkarni
Sanjeev Anant Kulkarni
Dipak Raychand Lagad
Prathap Sreedharan Nair
Venkata P Palle
Chetan Sanjay Pawar
Sachin Sethi
Milind Dattatraya Sindkhedkar
Mahadeo Bhaskar Tryambake
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CU20200051A7 publication Critical patent/CU20200051A7/es
Publication of CU24621B1 publication Critical patent/CU24621B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

<p>La invención se refiere a compuestos heterocíclicos bicíclicos sustituidos de fórmula (I), a sales farmacéuticamente aceptables de los mismos y a composiciones farmacéuticas que comprenden al menos un compuesto de fórmula (I).</p>
CU2020000051A 2017-12-13 2018-12-13 Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 CU24621B1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201721044886 2017-12-13
IN201821024634 2018-07-02
IN201821040029 2018-10-23
PCT/IB2018/060015 WO2019116302A1 (en) 2017-12-13 2018-12-13 Substituted bicyclic heterocyclic compounds as prmt5 inhibitors

Publications (2)

Publication Number Publication Date
CU20200051A7 true CU20200051A7 (es) 2021-03-11
CU24621B1 CU24621B1 (es) 2022-09-08

Family

ID=65036860

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000051A CU24621B1 (es) 2017-12-13 2018-12-13 Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5

Country Status (28)

Country Link
US (2) US11459330B2 (es)
EP (1) EP3724190B1 (es)
JP (1) JP7282778B2 (es)
KR (1) KR20200098598A (es)
CN (1) CN111712498B (es)
AU (1) AU2018385664B2 (es)
BR (1) BR112020011746A2 (es)
CA (1) CA3085259A1 (es)
CL (1) CL2020001576A1 (es)
CR (1) CR20200263A (es)
CU (1) CU24621B1 (es)
DK (1) DK3724190T3 (es)
ES (1) ES2927860T3 (es)
GE (1) GEP20227359B (es)
HR (1) HRP20221207T1 (es)
HU (1) HUE059945T2 (es)
IL (1) IL274936B2 (es)
LT (1) LT3724190T (es)
MX (1) MX2020006181A (es)
PE (1) PE20211444A1 (es)
PH (1) PH12020550881A1 (es)
PL (1) PL3724190T3 (es)
PT (1) PT3724190T (es)
RS (1) RS63623B1 (es)
SG (1) SG11202004934QA (es)
UA (1) UA126349C2 (es)
WO (1) WO2019116302A1 (es)
ZA (1) ZA202003528B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243178A1 (en) * 2019-05-30 2020-12-03 Angex Pharmaceutical, Inc. Heterocyclic compounds as prmt5 inhibitors
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
MX2021003819A (es) 2018-10-05 2021-06-23 Vertex Pharma Moduladores de alfa-1 antitripsina.
CA3134613A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
RS64972B1 (sr) * 2019-06-10 2024-01-31 Lupin Ltd Inhibitori prmt5
CN114599361A (zh) * 2019-10-22 2022-06-07 印度鲁宾有限公司 Prmt5抑制剂的药物组合物
JP2022553376A (ja) * 2019-10-25 2022-12-22 アクセント・セラピューティクス・インコーポレイテッド Ｍｅｔｔｌ３モジュレーター
WO2021111322A1 (en) 2019-12-03 2021-06-10 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
WO2021202480A1 (en) * 2020-04-01 2021-10-07 Aligos Therapeutics, Inc. Compounds targeting prmt5
WO2021203028A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
AU2022210517A1 (en) 2021-01-19 2023-07-27 Lupin Limited Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251431A1 (en) 2002-07-22 2004-02-09 Cambridge University Technical Services Ltd. Synthesis of discodermolide
WO2005016878A2 (en) 2003-08-13 2005-02-24 Isis Pharmaceuticals, Inc. METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
US20080045521A1 (en) 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
CN102369204A (zh) 2008-09-26 2012-03-07 新加坡科技研究局 3-脱氮瓶菌素衍生物
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
KR101789129B1 (ko) 2010-06-30 2017-11-20 후지필름 가부시키가이샤 신규 니코틴아미드 유도체 또는 그 염
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
WO2013028447A1 (en) 2011-08-19 2013-02-28 Glaxosmithkline Llc Fatty acid synthase inhibitors
JP6182593B2 (ja) * 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
PT2861604T (pt) 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
WO2014008223A2 (en) 2012-07-03 2014-01-09 Glaxosmithkline Llc Fatty acid synthase inhibitors
JP6678455B2 (ja) 2012-12-21 2020-04-08 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
US8906900B2 (en) 2012-12-21 2014-12-09 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9221794B2 (en) 2012-12-21 2015-12-29 Epizyme, Inc. PRMT5 inhibitors and uses thereof
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
JP6510485B2 (ja) 2013-03-15 2019-05-08 オハイオ・ステイト・イノベーション・ファウンデーション Ｐｒｍｔ５インヒビターおよびそれらの使用方法
KR20160076519A (ko) 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Kras g12c 억제제
CA2943882A1 (en) 2014-05-22 2015-11-26 F. Hoffmann-La Roche Ag Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives
EP3160477A4 (en) 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EA032017B1 (ru) 2014-06-25 2019-03-29 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Кристаллические соли (s)-6-((1-ацетилпиперидин-4-ил)амино)-n-(3-(3,4-дигидроизохинолин-2(1h)-ил)-2-гидроксипропил)пиримидин-4-карбоксамида
US20170210751A1 (en) 2014-06-25 2017-07-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016022605A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016034671A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
WO2016034673A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
EP3191592A1 (en) 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
TN2017000357A1 (en) 2015-02-24 2019-01-16 Pfizer Substituted nucleoside derivatives useful as anticancer agents
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) * 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
JP7015059B2 (ja) 2015-11-16 2022-02-15 アラクセス ファーマ エルエルシー 置換複素環式基を含む２－置換キナゾリン化合物およびその使用方法
EA201990851A1 (ru) * 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5

Also Published As

Publication number Publication date
IL274936A (en) 2020-07-30
PL3724190T3 (pl) 2022-10-31
US20220267339A1 (en) 2022-08-25
US11459330B2 (en) 2022-10-04
MX2020006181A (es) 2020-09-03
CN111712498A (zh) 2020-09-25
JP2021506793A (ja) 2021-02-22
PE20211444A1 (es) 2021-08-05
PT3724190T (pt) 2022-10-03
PH12020550881A1 (en) 2021-04-05
CU24621B1 (es) 2022-09-08
IL274936B1 (en) 2023-05-01
ZA202003528B (en) 2022-05-25
RS63623B1 (sr) 2022-10-31
AU2018385664A1 (en) 2020-07-02
EP3724190A1 (en) 2020-10-21
EP3724190B1 (en) 2022-07-06
CN111712498B (zh) 2023-09-29
ES2927860T3 (es) 2022-11-11
HUE059945T2 (hu) 2023-01-28
SG11202004934QA (en) 2020-07-29
DK3724190T3 (da) 2022-10-10
UA126349C2 (uk) 2022-09-21
US11952380B2 (en) 2024-04-09
CL2020001576A1 (es) 2020-11-06
HRP20221207T1 (hr) 2022-12-09
KR20200098598A (ko) 2020-08-20
AU2018385664B2 (en) 2022-06-02
CR20200263A (es) 2020-07-26
GEP20227359B (en) 2022-03-10
CA3085259A1 (en) 2019-06-20
LT3724190T (lt) 2022-10-10
BR112020011746A2 (pt) 2020-11-17
WO2019116302A1 (en) 2019-06-20
JP7282778B2 (ja) 2023-05-29
US20210163486A1 (en) 2021-06-03
IL274936B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
CU20200051A7 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
PH12018500425A1 (en) Novel 6-6 bicyclic aromatic ring substituted nuceloside analogues for use as prmt5 inhibitors
CU20210009A7 (es) Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3)
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CO2018008759A2 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CU20180019A7 (es) Derivados de heteroarilo como inhibidores de parp
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
EA201691302A1 (ru) Новые гетероциклические соединения
CR20150045A (es) Inhibidores de hepatitis c
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
UY35300A (es) Formulación de combinación de dos compuestos antivirales
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
CL2017003340A1 (es) Compuestos inhibidores de serina/treonina-proteína cinasa (tbk)/inhibidor de cinasa de factor nuclear kappa-b subunidad epsilon (ikk-epsilon) y sus usos de los mismos
EA201792021A1 (ru) Ингибитор jak
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CR20160557A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
MA50093B1 (fr) Composé pentacyclique